| 1 |
34671997 | Sub-therapeutic colchicine levels in a patient treated for acute pericarditis in the setting of carbamazepine use: A case report. | 2022 Apr |
1 |
| 2 |
32737897 | Drug-drug and drug-food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet. | 2021 Mar |
1 |
| 3 |
33671323 | Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach. | 2021 Feb 17 |
4 |
| 4 |
33756436 | Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis. | 2021 Jul |
4 |
| 5 |
34495458 | Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. | 2021 Nov |
1 |
| 6 |
32446424 | High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers. | 2020 Apr - Jun |
1 |
| 7 |
32910451 | [Carbamazepine and quetiapine: a neglected, but highly relevant interaction]. | 2020 |
1 |
| 8 |
33283769 | Presence of allele CYP3A4*16 does not have any bearing on carbamazepine-induced adverse drug reactions in North Indian people with epilepsy. | 2020 Sep-Oct |
2 |
| 9 |
30785734 | Allosteric Interactions in Human Cytochrome P450 CYP3A4: The Role of Phenylalanine 213. | 2019 Mar 12 |
2 |
| 10 |
32082165 | Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. | 2019 |
1 |
| 11 |
29384591 | A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. | 2018 May |
1 |
| 12 |
29569712 | Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. | 2018 Dec |
1 |
| 13 |
29649093 | Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker. | 2018 Aug |
3 |
| 14 |
29869546 | The Use of Carbamazepine to Expedite Metabolism of Risperidone Long-Acting Injection Through Induction of CYP3A4 in a Patient With Extrapyramidal Symptoms. | 2018 Jun 1 |
1 |
| 15 |
30581412 | Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. | 2018 |
1 |
| 16 |
27690733 | Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. | 2017 Oct |
6 |
| 17 |
27776366 | Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers. | 2017 Jan |
2 |
| 18 |
27821711 | Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized. | 2017 Jan |
1 |
| 19 |
28215696 | Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. | 2017 Mar - Apr |
2 |
| 20 |
29369597 | How long does the pharmacokinetic interaction between carbamazepine and quetiapine last after carbamazepine withdrawal? | 2017 Dec |
6 |
| 21 |
26574235 | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | 2016 Feb |
3 |
| 22 |
26651976 | Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs. | 2016 |
1 |
| 23 |
26711482 | Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells. | 2016 Sep |
1 |
| 24 |
26936324 | Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition. | 2016 Dec |
1 |
| 25 |
27274257 | Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. | 2016 |
1 |
| 26 |
27276192 | Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients. | 2016 Mar |
2 |
| 27 |
27402728 | CYP3A Specifically Catalyzes 1β-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity. | 2016 Sep |
1 |
| 28 |
27417180 | An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software. | 2016 Oct |
1 |
| 29 |
27450623 | Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. | 2016 Oct |
1 |
| 30 |
27650703 | Correction to Concurrent Cooperativity and Substrate Inhibition in the Epoxidation of Carbamazepine by Cytochrome P450 3A4 Active Site Mutants Inspired by Molecular Dynamics Simulations. | 2016 Oct 4 |
1 |
| 31 |
30085479 | EFFECT OF CARBAMAZEPINE ON THE ACTIVITY OF CYP3A4 ISOENZYME IN PATIENTS WITH ALCOHOL ADDICTION. | 2016 |
6 |
| 32 |
24898833 | Treatment of hypopituitarism in patients receiving antiepileptic drugs. | 2015 Feb |
2 |
| 33 |
25438721 | Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. | 2015 Feb 1 |
1 |
| 34 |
25545162 | Concurrent cooperativity and substrate inhibition in the epoxidation of carbamazepine by cytochrome P450 3A4 active site mutants inspired by molecular dynamics simulations. | 2015 Jan 27 |
12 |
| 35 |
25624269 | Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. | 2015 May |
2 |
| 36 |
25656284 | Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. | 2015 Mar |
3 |
| 37 |
26315684 | Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. | 2015 Oct |
1 |
| 38 |
26421491 | Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. | 2015 Nov |
1 |
| 39 |
26516577 | Applicability of second-generation upcyte® human hepatocytes for use in CYP inhibition and induction studies. | 2015 Oct |
1 |
| 40 |
24406279 | Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. | 2014 |
1 |
| 41 |
24691829 | Effect of Sophora flavescens on the pharmacokinetics of carbamazepine in rats. | 2014 Dec |
3 |
| 42 |
24695353 | Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity. | 2014 Jul |
5 |
| 43 |
24817818 | Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients. | 2014 |
2 |
| 44 |
24861996 | Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. | 2014 Aug |
1 |
| 45 |
25495409 | Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. | 2014 |
1 |
| 46 |
25561870 | Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin. | 2014 Dec |
1 |
| 47 |
23212742 | Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. | 2013 May |
1 |
| 48 |
23252947 | Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. | 2013 Jan |
2 |
| 49 |
23480152 | Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. | 2013 |
1 |
| 50 |
23716885 | Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals. | 2013 Mar-Apr |
1 |